So, what factors determine the successful approval of new therapeutics in the commercial sector? The literature on this is extensive, especially for the hit-to-lead optimisation phase. However, there is no magic formula since the ratios in Fig. have proved largely immovable. It may thus be more useful to firstly look at reasons for failure and secondly find examples of improvement strategies that have tangible evidence of a payoff.